Reported Earlier, BridgeBio's Acoramidis Shows 42% Reduction in Mortality and Heart Hospitalizations in ATTR-CM Study, New Drug Application Under FDA Review
Reported Earlier, BridgeBio's Acoramidis Shows 42% Reduction in Mortality and Heart Hospitalizations in ATTR-CM Study, New Drug Application Under FDA Review
據報道，BridgeBio的Acoramidis在ATTR-Cm研究中顯示心衰和心臟住院率降低42％，新藥申請正處於FDA審查中。
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases, presented a post-hoc analysis evaluating the effect of acoramidis on the composite endpoint of ACM and recurrent CVH events in its Phase 3 ATTRibute-CM study in ATTR-CM at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024. ATTRibute-CM was designed to evaluate the efficacy and safety of acoramidis, an investigational, near-complete, orally-administered, small molecule stabilizer of TTR.
BridgeBio Pharma, Inc.（納斯達克：BBIO）（「BridgeBio」或「公司」），一家專注於遺傳病的商業階段生物製藥公司，展示了對ACm和復發CVH事件的複合終點在其ATTR-Cm第3期ATTRibute-Cm研究中對acoramidis的影響的事後分析，該研究於2024年在美國心力衰竭協會（HFSA）年度科學會議上舉行。 ATTRibute-Cm旨在評估acoramidis的療效和安全性，這是一種調查性的近完整口服小分子TTR穩定劑。
"We are proud to share the results of this post-hoc analysis demonstrating a highly significant reduction in all...
「我們很自豪地分享了這項事後分析的結果...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。